(PharmaNewsWire.Com, August 12, 2017 ) This report provides an overview of the skeletal disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA) .
OA is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Postmenopausal osteoporosis is the most common subtype of osteoporosis, and affects many women after menopause. Signs and symptoms of osteoporosis include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and other osteoporosis medications.
The size of these pipelines ranges from 13 products in postmenopausal osteoporosis to 116 in OA. The predominant targets within OA are prostaglandin G/H synthases 1 and 2, although a wide range of targets, including extracellular matrix-organizing proteins and interleukins, are being studied. Likewise, within both osteoporosis and the post-menopausal subtype, a broad range of molecular targets are being studied. The targets being most frequently studied are the parathyroid hormone receptor, tumor necrosis factor ligand superfamily member 11 and sclerostin.
Scope - Which companies are the most active within the pipeline for osteoporosis and OA therapeutics? - Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened in the field of osteoporosis and OA therapeutics?
Reasons to buy - Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication - Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each - Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these - Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents Publisher Report Guidance 2 Executive Summary 3 Table of Contents 4 List of Tables 5 List of Figures 9 Introduction 10 Skeletal Disease Report Coverage 10 Osteoarthritis - Overview 10 Osteoporosis - Overview 10 Post Menopausal Osteoporosis - Overview 10 Therapeutics Development 11 Osteoarthritis 11 Osteoporosis 21 Post Menopausal Osteoporosis 31 Therapeutics Assessment 34 Osteoarthritis 34 Osteoporosis 44 Post Menopausal Osteoporosis 54 Companies Involved in Therapeutics Development 62 Osteoarthritis 62 Osteoporosis 96 Post Menopausal Osteoporosis 124 Dormant Projects 129 Osteoarthritis 129 Osteoporosis 133 Post Menopausal Osteoporosis 138 Discontinued Products 139 Osteoarthritis 139 Osteoporosis 140 Post Menopausal Osteoporosis 141 Product Development Milestones 142 Osteoarthritis 142 Osteoporosis 154 Post Menopausal Osteoporosis 164 Appendix 175 Methodology 175 Coverage 175 Secondary Research 175 Primary Research 175 Expert Panel Validation 175
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: